Sulforaphane and NRF2: What Human Trials Actually Show

Broccoli sprouts can plausibly switch on NRF2, a cellular stress-response program that increases production of detoxification and antioxidant enzymes. Human trials have tested that idea in the mouth and airway tissue of smokers and in the skin of healthy adults. The catch is substantial: these studies measure biomarkers, not fewer cancers, younger-looking skin, better physical function, or longer life.

That distinction matters because NRF2 is not a universal health dial. In healthy cells facing oxidative stress, its activity may help coordinate protective responses. In established lung cancer, however, higher NRF2-pathway activity predicts worse prognosis and may help malignant cells resist treatment. The biology is interesting; the clinical recommendation remains narrow.

What sulforaphane does—and why broccoli sprouts matter

Sulforaphane is an isothiocyanate made when glucoraphanin, a glucosinolate found in broccoli sprouts and other cruciferous vegetables, is converted by the enzyme myrosinase. Sulforaphane reacts with KEAP1, a protein that normally restrains NRF2. When that restraint loosens, NRF2 can increase expression of genes involved in antioxidant defenses and phase II detoxification, including NQO1, heme oxygenase-1, glutathione S-transferases, and enzymes that support glutathione production. Reviews of the pathway describe it as a central defense against oxidative and electrophilic stress, although its effects depend on tissue and disease context.

Food chemistry complicates every practical claim. Plant damage brings glucoraphanin and myrosinase together, but heat can degrade myrosinase. Gut microbes can also contribute to conversion, with large person-to-person variation. As Fahey and colleagues explain in their review of broccoli-sprout trials, differences in preparation, formulation, dose delivery, and metabolism make one supplement label a poor proxy for the amount of sulforaphane that reaches a person's tissues.

The best airway study tested detoxification markers, not cancer prevention

The most rigorous trial in this group was an NCI-sponsored, open-label randomized 2×2 crossover study in at least 41 evaluable current heavy smokers: participants had smoked at least 20 pack-years and at least 10 cigarettes per day. In Bauman et al.'s 2023 trial, participants received glucoraphanin doses of 148 or 296 µmol per day for two weeks, separated by a two-week washout. The investigators estimated those doses would yield roughly 50 or 100 µmol of sulforaphane, respectively.

The tablets included food-grade myrosinase, an important design choice because it reduces reliance on variable microbial conversion. Under those study conditions, estimated glucoraphanin-to-sulforaphane conversion was about 35%. That figure should not be treated as a general conversion rate for cooked broccoli, raw sprouts, or every supplement.

The trial's primary outcome was the urinary profile of mercapturic acids from tobacco carcinogens, including metabolites related to benzene, acrolein, and crotonaldehyde. Buccal-cell NQO1 messenger RNA and dose-response across NRF2 target genes were prespecified secondary outcomes. A crossover design helps limit the noise created by differences in baseline metabolism between people, but it does not turn urinary metabolites or gene expression into evidence that supplementation prevents lung cancer.

The study also prespecified GSTM1 and GSTT1 null genotypes as potential effect modifiers. These genes affect glutathione-related sulforaphane metabolism, so the same glucoraphanin dose may not produce the same biological response in every participant. The open-label design creates another limitation, particularly for outcomes that behavior could influence. A two-week washout may also be too short to establish a fully independent baseline in people with continuing tobacco exposure.

A skin pilot asked a useful question with very little statistical room

Chien et al.'s 2025 randomized trial moved the question to skin. Eighteen healthy adults with skin types I–II took glucoraphanin alone, curcumin alone, or both for 10 days; each arm included six people. The glucoraphanin dose was 1,030 µmol per day, about 3.5 times the higher dose used in the smoker trial.

Researchers measured cytoprotective gene expression in skin punch biopsies, collected urinary sulforaphane metabolites as a compliance marker, and attempted to detect sulforaphane metabolites directly in skin tissue. Direct tissue measurement is a sensible test of whether an oral precursor reaches skin at all. Yet the publication details available here do not provide quantitative skin concentrations, half-life, or tissue exposure over time. They also do not establish that any gene-expression change improves skin health or prevents skin cancer.

Six participants per group makes this a hypothesis-generating pilot, not a reliable head-to-head verdict on glucoraphanin, curcumin, or their combination. The combination arm adds a further problem: curcumin has also been reported as an NRF2-active phytochemical, so any combined effect cannot cleanly identify sulforaphane's contribution. The approximately 35% conversion estimate from the smoker study cannot simply be multiplied by this much higher dose; different formulations, populations, and enzyme conditions can produce different exposure.

Aging provides rationale, not a sulforaphane result

Older adults may have less capacity to recover from an oxidative challenge even when their resting biomarkers look similar to those of younger adults. In Rodriguez et al.'s 2025 study, 20 healthy younger adults (mean age 25 ± 4 years) and 20 healthy older adults (mean age 70 ± 6 years) underwent a standardized forearm ischemia/reperfusion challenge. Resting plasma F2-isoprostanes, markers of lipid peroxidation, did not differ significantly between groups (p=0.34).

After the challenge, the older group had a greater and more prolonged F2-isoprostane response. Area-under-the-response-curve values differed significantly from 60 minutes onward (p<0.05), and values in older adults remained elevated while the younger group returned to baseline. This supports the narrower conclusion that aging can impair recovery from an oxidative stress challenge.

It does not show that sulforaphane corrected that impairment. The available results do not report a sulforaphane intervention, dose, or intervention effect in this cohort. Nor did the study directly measure NRF2 nuclear translocation or target-gene expression in aged human tissue. The link to declining NRF2 functional reserve is biologically coherent, but it remains an interpretation rather than direct proof from this experiment.

NRF2 has a cancer problem

NRF2 activity can protect healthy cells, but cancer cells can exploit the same defenses. Ungvari et al. reported in 2025 that NRF2-pathway activation predicted poor prognosis in established lung cancer, consistent with greater resistance to chemotherapy and radiotherapy. This is especially relevant to heavy smokers, who face elevated risk of occult lung cancer.

That finding does not prove that broccoli sprouts cause cancer progression or worsen treatment outcomes. It does mean that "antioxidant pathway activation" is not automatically desirable in someone with active, suspected, or recently treated malignancy. The context-dependent behavior of NRF2 also appears in preclinical work: a mouse study found that sulforaphane could worsen carbon-nanotube-associated lung inflammation under a specific experimental exposure. That mouse study cannot predict effects of dietary sprouts in people, but it argues against treating NRF2 as a one-way protection switch.

Where this leaves broccoli sprouts

A systematic review of human dietary-phytochemical NRF2 trials places sulforaphane among the best-characterized food-derived NRF2 activators. Within the studies discussed here, glucoraphanin-derived sulforaphane has randomized human research aimed at pathway-related endpoints in more than one tissue context. That is a meaningful research advantage over many wellness ingredients whose claims never leave a cell dish.

It is still mechanistic evidence. No trial here measured cancer incidence, skin-cancer prevention, physical function, or a clinical aging outcome. No confidence intervals or quantitative effect estimates for the central biomarker results are available in the reported details, so claims about the size or reliability of those changes would overreach.

For healthy adults, broccoli sprouts are a food-based way to explore a plausible NRF2 mechanism, not a proven anti-aging or cancer-prevention treatment. People with active or suspected cancer should discuss concentrated sulforaphane or glucoraphanin supplements with their oncology team before using them.